MedTrace Logo

Buccal Versus Vaginal Misoprostol in Surgical Termination of the First Trimester Missed Abortion in Erbil

NCT00892229 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2009-05-04

No results posted yet for this study

Summary

The purpose of this study is to determine the effectiveness of buccal misoprostol and comparing this with vaginal route of the same drug.

Conditions

  • Missed Abortion

Interventions

DRUG

Misoprostol (given buccally)

400 microgram misoprostol given buccally three hours before dilation and curettage (PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)

DRUG

Misoprostol (given vaginally)

400 microgram misoprostol (MISOPROSTOL - PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)

Sponsors & Collaborators

  • NEGATIVE

    collaborator AMBIG

  • Hawler Medical University

    lead OTHER

Principal Investigators

  • BASHAR Y F HANOOSHI, CABOG · IRAQI MEDICAL SPECIALIZATION/IRAQ

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-01-31
Completion
2008-03-31

Countries

  • Iraq

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00892229 on ClinicalTrials.gov